关于缔脉
缔脉生物医药科技(上海)有限公司是一家立足中国、面向全球的临床合同研究组织(CRO)。员工中有很多是跨国药企的行业精英和中美两国医药监督管理机构的权威专家,借助多年丰富的药物开发经验,从方案设计到申报策略、从运营执行到质量保证,为客户提供更有价值的建议和更可靠的运营管理,为中国及全球生物医药公司和医疗器械公司提供高质量高水准全方位的临床服务,从而提高客户临床研发的效率,缩短研发的周期,提高研发成功的几率。
我们的主营业务包括专家咨询、药政事务与策略、早期开发及临床药理、临床科学与医学事务、临床试验运营、生物统计、临床编程、数据管理、药物安全与警戒、质量保证与临床稽查和系统支持等。
我们的员工覆盖包括上海、北京、武汉、广州、成都、纽约、华盛顿、旧金山和布鲁塞尔等地,全球员工数逾600人,其中60%以上具有硕士或以上学历,五分之一员工有10年以上工作经验。
About dMed
dMed is a full-service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe. dMed is led by experts in China and the US who originated from leading multinational pharma companies and regulatory agencies. We are uniquely positioned to leverage and integrate China’s new regulatory framework, offer innovative drug development strategies, and help our clients expand globally by tapping into the world’s second largest pharmaceutical market. Our creative and flexible collaboration models will help Chinese and global innovative pharma companies effectively raise efficiency in clinical R&D, scientifically shorten research cycle, and boost success rate.
Our business covers consulting, early development & clinical pharmacology, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, clinical science & medical affairs, quality assurance, regulatory affairs and strategy.
dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs more than 600 professionals globally, among them 60% holds master above degree and 20% with more than 10 years working experiences.
缔脉生物医药科技(上海)有限公司是一家立足中国、面向全球的临床合同研究组织(CRO)。员工中有很多是跨国药企的行业精英和中美两国医药监督管理机构的权威专家,借助多年丰富的药物开发经验,从方案设计到申报策略、从运营执行到质量保证,为客户提供更有价值的建议和更可靠的运营管理,为中国及全球生物医药公司和医疗器械公司提供高质量高水准全方位的临床服务,从而提高客户临床研发的效率,缩短研发的周期,提高研发成功的几率。
我们的主营业务包括专家咨询、药政事务与策略、早期开发及临床药理、临床科学与医学事务、临床试验运营、生物统计、临床编程、数据管理、药物安全与警戒、质量保证与临床稽查和系统支持等。
我们的员工覆盖包括上海、北京、武汉、广州、成都、纽约、华盛顿、旧金山和布鲁塞尔等地,全球员工数逾600人,其中60%以上具有硕士或以上学历,五分之一员工有10年以上工作经验。
About dMed
dMed is a full-service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe. dMed is led by experts in China and the US who originated from leading multinational pharma companies and regulatory agencies. We are uniquely positioned to leverage and integrate China’s new regulatory framework, offer innovative drug development strategies, and help our clients expand globally by tapping into the world’s second largest pharmaceutical market. Our creative and flexible collaboration models will help Chinese and global innovative pharma companies effectively raise efficiency in clinical R&D, scientifically shorten research cycle, and boost success rate.
Our business covers consulting, early development & clinical pharmacology, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, clinical science & medical affairs, quality assurance, regulatory affairs and strategy.
dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs more than 600 professionals globally, among them 60% holds master above degree and 20% with more than 10 years working experiences.
Location: China, Shanghai
Employees: 501-1000
Total raised: $158M
Founded date: 2016
Investors 3
| Date | Name | Website |
| - | Qiming Ven... | qimingvent... |
| - | Vivo Capit... | vivocapita... |
| 09.10.2022 | Qiming Ven... | qimingvc.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.12.2020 | Series C | $100M | - |
| 16.10.2019 | Series B | $50M | - |
| 02.12.2016 | Series A | $8M | - |
Mentions in press and media 13
| Date | Title | Description |
| 12.07.2021 | In Didi’s crackdown, the battle for new oil is on | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The founders of China’s largest ride-sharing operation had less than a week to revel in their new... |
| 10.07.2021 | dMed-Clinipace Closes US$50M Series C+ Financing | dMed-Clinipace, a Shangai, China- and Morrisville, NC-based global full-service Clinical Contract Research Organization (CRO), closed a US$50m Series C+ financing. The round was led by Springhill Fund, with participation from funds managed ... |
| 07.07.2021 | dMed-Clinipace Announces Completion of US$50 Million Series C+ Financing from New Investors | SHANGHAI and MORRISVILLE, N.C., July 7, 2021 /PRNewswire/ -- dMed-Clinipace, the global full-service Clinical Contract Research Organization (CRO), announced today the recent successful completion of a US$50 million Series C+ financing with... |
| 21.05.2021 | Recently Merged dMed and Clinipace Announce the Appointment of New Global COO | SHANGHAI and MORRISVILLE, N.C., May 21, 2021 /PRNewswire/ -- Following the recent merger announcement of Shanghai-based dMed Global and NC-based Clinipace Incorporated, the combined company today announced the appointment of Simon Britton t... |
| 19.12.2020 | dMed Completed a US$100 Million Series C Financing | - |
| 17.12.2020 | Fidelity leads $100m Series C round in China-based clinical CRO dMed | Premium dMed Biopharmaceutical, a clinical contract research organisation (CRO) with operations in China and the US, announced on Thursday that it has raised $100 million in a Series C round of financing led by Fidelity Management & Res... |
| 17.12.2020 | Fidelity leads $100m Series C round in China-based clinical CRO dMed | dMed Biopharmaceutical, a clinical contract research organisation (CRO) with operations in China and the US, announced on Thursday that it has raised $100 million in a Series C round of financing led by Fidelity Management & Research Co... |
| 17.12.2020 | dMed Closes US$100M Series C Financing | dMed, a Shangai, China-based clinical CRO, completed a US$100m Series C financing. The round was led by Fidelity Management & Research Company, LLC, with participation from new investors Sequoia Capital China, Kaiser Foundation Hospital... |
| 17.10.2019 | Legend Capital, Qiming back Chinese CRO startup dMed’s $50m Series B | Premium Chinese clinical contract research organization (CRO) dMed Biopharmaceutical has raised 354 million yuan ($50 million) in a Series B round led by Vivo Capital, according to a media statement. Continue reading this story with a subsc... |
| 16.10.2019 | dMed Secures Nearly US$50M in Series B Financing | dMed and investors signed the financing documents dMed Biopharmaceutical Co., Ltd., a Shangai, China-based full service Clinical Contract Research Organization (CRO), completed a nearly US$50m Series B financing. The round was led by Vivo C... |
Show more